Afficher la notice abrégée

dc.rights.licenseopenen_US
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorLETINIER, Louis
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorCOSSIN, Sebastien
IDREF: 197817874
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorMANSIAUX, Yohann
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorARNAUD, Mickael
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorSALVO, Francesco
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorBEZIN, Julien
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorTHIESSARD, Frantz
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorPARIENTE, Antoine
IDREF: 13395711X
dc.date.accessioned2020-06-26T08:45:11Z
dc.date.available2020-06-26T08:45:11Z
dc.date.issued2019-03
dc.identifier.issn1663-9812 (Print) 1663-9812 (Linking)en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/8214
dc.description.abstractEnIntroduction: Drug interactions could account for 1% of hospitalizations in the general population and 2-5% of hospital admissions in the elderly. However, few data are available on the drugs concerned and the potential severity of the interactions encountered. We thus first aimed to estimate the prevalence of dispensings including drugs Contraindicated or Discommended because of Interactions (CDI codispensings) and to identify the most frequently involved drug pairs. Second, we aimed to investigate whether the frequency of CDI codispensings appeared higher or lower than the expected for the drugs involved. Methods: We carried out a study using a random sample of all drugs dispensings registered in a database of the French Health Insurance System between 2010 and 2015. The distribution of the drugs involved was described considering active principles, detailing the 20 most frequent ones for both contraindicated or discommended codispensings (DCs). To investigate whether the frequency of CDI codispensings appeared higher or lower than the expected for the drugs involved, we developed a specific indicator, the Drug-drug interaction prevalence study-score (DIPS-score), that compares for each drug pair the observed frequency of codispensing to its expected probability. The latter is determined considering the frequencies of dispensings of the individual drugs constituting a pair of interest. Results: We analyzed 6,908,910 dispensings: 13,196 (0.2%) involved contraindicated codispensings (CCs), and 95,410 (1.4%) DCs. For CCS, the most frequently involved drug pair was "bisoprolol+flecainide" = 5,036); four out of five of the most represented pairs involved cardiovascular drugs. For DCS, the most frequently involved drug pair was "ramipril+spironolactone" = 4,741); all of the five most represented pairs involved cardiovascular drugs. The drug pair involved in the CC with the highest score value was "citalopram+hydroxyzine" (DIPS-score: 3.7; 2.9-4.6); that with the lowest score was "clarithromycin+simvastatin" (DIPS-score: 0.2; 0.2-0.3). DIPS-score median value was 0.4 for CCs and 0.6 for DCs. Conclusion: This high prevalence of CDI codispensings enforces the need for further risk-prevention actions regarding drug-drug interactions (DDIs), especially for arrhythmogenic or anti-arrhythmic drugs. In this perspective, the DIPS-score we develop could ease identifying the interactions that are poorly considered by clinicians/pharmacists and targeting interventions.
dc.language.isoENen_US
dc.rightsAttribution 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/us/*
dc.subject.enPharmacoEpi-Drugs
dc.subject.enERIAS
dc.subject.enFR
dc.title.enRisk of Drug-Drug Interactions in Out-Hospital Drug Dispensings in France: Results From the DRUG-Drug Interaction Prevalence Study
dc.typeArticle de revueen_US
dc.identifier.doi10.3389/fphar.2019.00265en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed30967779en_US
bordeaux.journalFrontiers in Pharmacologyen_US
bordeaux.page265en_US
bordeaux.volume10en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - U1219en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.identifierhal-03211472
hal.version1
hal.date.transferred2021-04-28T15:17:32Z
hal.exporttrue
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Frontiers%20in%20Pharmacology&rft.date=2019-03&rft.volume=10&rft.spage=265&rft.epage=265&rft.eissn=1663-9812%20(Print)%201663-9812%20(Linking)&rft.issn=1663-9812%20(Print)%201663-9812%20(Linking)&rft.au=LETINIER,%20Louis&COSSIN,%20Sebastien&MANSIAUX,%20Yohann&ARNAUD,%20Mickael&SALVO,%20Francesco&rft.genre=article


Fichier(s) constituant ce document

Thumbnail
Thumbnail

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée